0001437749-26-017821
SEC filingMonopar Therapeutics announced publication of a Phase 2 study in Hepatology Communications demonstrating that ALXN1840 significantly improves copper balance in Wilson disease patients.
The 8-K filing and accompanying press release detail a peer-reviewed publication of an open-label Phase 2 trial (NCT04573309) evaluating ALXN1840 in nine Wilson disease patients. The study met its primary endpoint of improving daily copper balance, driven by fecal excretion, with statistical significance. Importantly, these improvements occurred in patients with a mean prior standard-of-care duration of 16 years, suggesting ALXN1840 can mobilize residual copper. The data reinforce the drug's potential as a new treatment option for Wilson disease, a rare genetic disorder characterized by toxic copper accumulation. No financial guidance or changes to corporate structure were disclosed.